Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >= years Patients with a history of any malignancy are ineligible History of prior malignancy, except (Criteria a through f): History of other malignancy within years prior to screening History of another malignancy within years of the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for years. Prior other malignancy within years (except for in situ disease, which is permissible). Patients who have a history of another primary malignancy that has been diagnosed or required therapy within years before randomization. History of another malignancy except for: Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > months prior and/or bone marrow transplant > years prior Other malignancy requiring treatment in the prior years History of malignancy other than NSCLC within years prior to screening Have a history of another primary malignancy, with the exception of: Has history of other active malignancy within years prior to enrollment, except: Patients must not have received treatment for another malignancy within years of enrollment Prior malignancy or therapy for a malignancy within years Participants with presence of other active malignancy within years of study entry; participants with history of prior malignancy treated with curative intent and achieved CR within years are eligible. Other malignancy within years prior to screening, with some exceptions Active malignancy besides NSCLC within years prior to screening. No prior history of malignancy within years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within years Subjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed > years ago that has undergone potentially curative therapy with no evidence of disease for the last >= years and that is deemed by the investigator to be at a low risk of recurrence History of malignancy other than their lymphoma with the exception of: Has a history of another malignancy. Patients with prior malignancy and treated with no evidence of active disease, and more than years from initial diagnosis are eligible History of other malignancy within the last years (with exceptions). Participants with a history of other malignancy within years prior to screening A history of other malignancy =< years previous which would preclude endocrine treatment of their cancer No active prior malignancy within years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between - years, special consideration can be requested; in these cases, if the risk of recurrence at years is less than %, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principal investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least years will be eligible History of another primary invasive malignancy that has not been definitively treated or in remission for at least years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses); if patients have another malignancy that was treated within the last years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within years is less than %, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the principal investigator Previous chemotherapy for any malignancy, if given within three years of registration Other malignancy within five years, except the following may be eligible: Patients with a history of any other malignancy, except patients with a secondary brain tumor if the patients first malignancy has been in remission for at least years from the end of treatment No chemotherapy for a malignancy in the last years Concurrent malignancy or history of other malignancy within the last five years except as noted above History of a non-lymphoid malignancy except for protocol allowed exceptions History of malignancy; History of another primary malignancy History of another primary malignancy that has not been in remission for at least years. An active second malignancy or history of another malignancy within the last years, with exceptions. Malignancy within the last years History of concurrent malignancy requiring active therapy or prior history of another malignancy within years. Patients with a history of another malignancy within years of study enrollment Individuals with a history of a previous malignancy are ineligible; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than years prior to registration may be enrolled History of other malignancy within years prior to screening Presence of malignancy other than the study indication under this trial within years of study enrollment History of prior malignancy History of prior malignancy, with the exception of the following: Patients who have a history of any hematopoietic malignancy History of prior malignancy except: History of other malignancy within the last years Have a concurrent malignancy or had another malignancy within years (? years) of study enrollment. Known history of another primary malignancy that has not been in remission for ? years Evidence within the last years of another malignancy which required systemic treatment History of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past years will be allowed. Have prior malignancy active within the previous years; Subject has a history of a malignancy (other than the disease under treatment in the study) within years before first study treatment administration There is any evidence of other malignancy being present within the last three years; Patient has a history of hematological malignancy within the last years prior to study entry History of another malignancy within years Other malignancy within the last years Patients with another primary malignancy that has not been in remission for at least years. History of any other malignancy History of another primary malignancy Other malignancy within years prior to Day of the study, except for those treated with surgical intervention only. Patients with a history of any other malignancy will not be eligible History of hematologic or primary solid tumor malignancy, unless no evidence of that disease for years History of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unless Prior history of metastatic malignancy Other malignancy within five years, except that the following may be eligible: Actively being treated for other malignancy; if there is a history of prior malignancy, patient must not be receiving other specific treatment for their cancer Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for years Presence of malignancy other than the study indication under this trial within years of study enrollment History of metastatic malignancy in the preceding years Participants with history of another primary malignancy not in remission for at least years History of metastatic malignancy in the preceding years Diagnosis of another malignancy within years before first dose of study treatment. History of prior malignancy within years; patients who are considered no evidence of disease (NED) from a malignancy may be considered on a case by case basis Other malignancy within the last years (few exceptions apply); History of another primary malignancy that has not been in remission for at least years History of other active malignancy within the prior years Has a history of a malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for years Any history of another metastatic malignancy Presence of any other malignancy or history of prior malignancy within years of study entry; within years, patients treated for stage I or II cancers are eligible provided they have a life expectancy > years in relation to this prior malignancy; the -year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer the malignancy has been in remission without treatment for ? years prior to enrollment, or History of another primary malignancy that has not been in remission for years History of another malignancy within years prior to starting study treatment Prior history of other malignancy except: History (within years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small (<% in years in the judgment of the investigator). Patients with a completely treated prior malignancy with no evidence of disease for ? years are eligible Active malignancy other than SCLC within the previous years History of another malignancy, some exceptions may apply. History of malignancy other than ALL within years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease No history of any hematopoietic malignancy History of another malignancy within the previous years; History of another primary malignancy that has not been in remission for at least years History of any hematopoietic malignancy History of a primary bone malignancy involving the lumbar spine Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least years prior to randomization Patients may have a history of other prior malignancy History of previous systemic chemotherapy unless given curatively for other malignancy now > years without evidence of recurrence Participants has a history of hematological malignancy within the last years prior to study entry Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within years of registration; if the original histologic proof of malignancy is greater than years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease) Another malignancy within years Non-hematologic malignancy within prior three () years. Has history of other active malignancy within years prior to enrollment, except: History of malignancy (other than the disease that required the HCT) within years prior to screening. Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for years Women with a history of a prior malignancy History of gynecologic malignancy that is estrogen dependent